Biotech Medics Ne (BMCS) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of Biotech Medics Ne $0.00, price $0.00, upside +0.0%, quality 43 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Biotech Medics Ne for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
BioTech Medics, Inc. operates as a medical-based holding company. The company operates medical therapeutic laser centers that treat various pain ailments affecting the muscles, nerves, and bones, as well as arthritis. It also offers SHBAN, an antiseptic hand and body sanitizer.
Show more
BioTech Medics, Inc. operates as a medical-based holding company. The company operates medical therapeutic laser centers that treat various pain ailments affecting the muscles, nerves, and bones, as well as arthritis. It also offers SHBAN, an antiseptic hand and body sanitizer. In addition, the company develops and sells nutraceutical products, such as BioBody Balance, a liquid vitamin concentrate; and BioBody Energy Spray, a caffeine and alcohol free natural vitamin energy spray. It offers its nutraceutical products through gross retail sales. The company was incorporated in 1997 and is based in Southlake, Texas with laser pain centers in Texas, California, New Mexico, and Florida.
Stock analysis
Biotech Medics Ne (BMCS) currently trades at $0.0002, while our model-based Fair Value estimate is $0.0002, so the stock looks roughly fairly valued today (gap 0.0%).
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of $0.0007 per share, and 1 of the 3 models we run sit above the $0.0002 price.
Bear case: the DCF Models group reads lowest at $0.0002, and 2 of the 3 models stay below the price. Evidence for this calculation is low.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Biotech Medics Ne reported revenue of $470K in FY2011 versus $477K in FY2008, a compound −0.5%/yr. Reported net income was −$2.9K in FY2024.
Key figures
Market cap $61.6K · P/S ratio 0.13 · EPS (TTM) $−0.0040 · Net margin −129% · Return on assets (EBIT) −8,075% · Operating margin −1,352% · Revenue (TTM) $470K · Free cash flow −$26.9K.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).
What moves the price
The share trades about 98% below its 52-week high and 100% above its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 0%, BMCS screens cheaper than that median.
Fair Value models
Bear $0.0002Fair Value $0.0002Bull $0.0002
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2024 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 585 stocks
Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score43 · Below median
Fair Value upside+0.0% · Above median
Profitability
Return on assets0.0% · Below median
Net margin (TTM)−128.5% · Bottom 25%
Growth and dividend
Revenue growth0.0% · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Biotech Medics Ne Fair Value". https://www.fairvalue-calculator.com/stock/BMCS
Frequently asked questions
Is Biotech Medics Ne (BMCS) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.0002 versus the last price from Sep 25, 2026 of $0.0002, about +0% upside (fairly valued).
What is the fair value of BMCS?
Our model-based fair value for Biotech Medics Ne is $0.0002 (as of Sep 27, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.0002.
What is the quality score of BMCS?
Biotech Medics Ne has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Biotech Medics Ne (BMCS)?
Our model-based price target is the fair value of $0.0002 (as of Sep 27, 2026) from 3 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Biotech Medics Ne stock forecast for 2026?
Our models put fair value at $0.0002, about +0% upside versus the last price from Sep 25, 2026 of $0.0002 (fairly valued). The calculation is refreshed regularly with new filings.
What is the revenue of Biotech Medics Ne (BMCS)?
Biotech Medics Ne reported trailing-twelve-month revenue of about $470K (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Biotech Medics Ne (BMCS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Biotech Medics Ne it is $0.0002 per share (as of Sep 27, 2026), against a price of $0.0002. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Biotech Medics Ne stock overvalued or undervalued in 2026?
As of Sep 27, 2026, BMCS trades below its calculated fair value: price $0.0002, fair value $0.0002, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BMCS?
No. The price is what the market pays today ($0.0002); the fair value is what the company's own numbers justify ($0.0002). For Biotech Medics Ne the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Biotech Medics Ne worth?
The market values Biotech Medics Ne at about $61.6K (market capitalisation, as of Sep 27, 2026). Per share that is $0.0002; our models calculate a fair value of $0.0002 per share.
How far is BMCS from its 52-week high?
Biotech Medics Ne trades at $0.0002, about 98% below its 52-week high of $0.0085 and 100% above the low of $0.0001 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0002 is for.
Which stocks are comparable to Biotech Medics Ne?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Biotech Medics Ne stock attractive at the current price?
The data as of Sep 27, 2026: price $0.0002, calculated fair value $0.0002 (+0%), Quality Score 43/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BMCS calculated?
We run Biotech Medics Ne through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0002, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Biotech Medics Ne itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Biotech Medics Ne (BMCS)?
The latest price we hold is from Sep 25, 2026 and stands at $0.0002. Our model-based fair value is $0.0002, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Biotech Medics Ne right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Biotech Medics Ne
How large is the market capitalisation of Biotech Medics Ne (BMCS)?
The market capitalisation of Biotech Medics Ne is $61.6K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Biotech Medics Ne (BMCS)?
The price-to-sales ratio of Biotech Medics Ne is 0.13 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Biotech Medics Ne (BMCS)?
Earnings per share at Biotech Medics Ne are $−0.0040. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Biotech Medics Ne (BMCS)?
The net margin of Biotech Medics Ne is −129% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Biotech Medics Ne (BMCS)?
On an EBIT basis the return on assets of Biotech Medics Ne is −8,075% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Biotech Medics Ne (BMCS)?
The operating margin of Biotech Medics Ne is −1,352% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Biotech Medics Ne (BMCS) generate?
The free cash flow of Biotech Medics Ne is −$26.9K (fiscal year 2023). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Biotech Medics Ne (BMCS) carry?
The net debt of Biotech Medics Ne is $2.0K (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Biotech Medics Ne in the live analysis
One click puts Biotech Medics Ne on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 27, 2026